吉非替尼维持治疗老年晚期肺腺癌的疗效研究  

Maintenance Therapy with Gefitinib for Elderly Patients in Advanced Adenocarcinoma of Lung

作　　者：刘晓梅[1] 张银旭[2] 刘恒 朱志图[1] 哈敏文[1] 

机构地区：[1]辽宁医学院附属第一医院肿瘤内科,辽宁锦州121000 [2]辽宁医学院附属第一医院大肠外科,辽宁锦州121000 [3]辽河油田第二职工医院肿瘤科

出　　处：《肿瘤防治研究》2011年第4期444-446,共3页Cancer Research on Prevention and Treatment

摘　　要：目的评价老年晚期肺腺癌患者诱导化疗后给予吉非替尼单药维持治疗的临床价值。方法 2006年1月—2008年6月,老年晚期肺腺癌患者最后一次化疗结束后疗效为部分缓解(PR)或稳定(SD)的为吉非替尼维持治疗组,疾病复发后为吉非替尼二线治疗组。入组后给予口服吉非替尼250mg/d,持续服用到疾病进展或死亡。结果共有40例患者入组,其中吉非替尼维持治疗组为21例,二线治疗组为19例。维持治疗组总有效率(RR)52.38%(11/21),其中1例CR,二线治疗组RR为21.05%(4/19),两组之间差异有统计学意义(P<0.05)。吉非替尼维持治疗组的中位总生存时间(OS)为16.19月,显著长于二线治疗组的7.90月(P<0.05)。结论吉非替尼维持治疗老年晚期肺腺癌患者有较好的近期疗效和生存益处。Objective To evaluate the efficacy of using gefitinib as maintenance therapy after chemotherapy.Methods Patients achieved partial response or disease stabilization following the last chemotherapy was devided into maintenance group.Gefitinib was administered at the dose of 250 mg/d.Results From Jan.2006 to Jun.2008,we enrolled 40 patients.Response rate to gefitinibwas 52.38%（11/21） in maintenance group and 21.05%（4/19） in control group（P0.05）,respectively.In comparison with control group,patients in maintenance group had longer time to survival（median OS ： 16.19 months vs.7.90 months,（P0.05）.The toxicity profile was mild and there was no significant difference between two groups.Conclusion Maintenance therapy with gefitinib was feasible and safe,which produced significantly longer OS of elderly patients with advanced lung adenocarcinoma.

关 键 词：吉非替尼 肺腺癌 维持治疗 老年 

分 类 号：R734.2[医药卫生—肿瘤]